A quasi-randomized clinical trial of tapentadol versus oxycodone for initial control of moderate cancer-related pain

A quasi-randomized clinical trial of tapentadol versus oxycodone for initial control of moderate cancer-related pain - A comparison of tapentadol and oxycodone for cancer pain

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000018954

Enrollment

Registered

2015-09-09

Start date

2015-09-09

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malignant neoplasm

Interventions

Oral tapentadol (50-200 mg/day) was given until the initial sign of signify analgesia was detected by patients. Oxycodone (10-40 mg) was given until the initial signs of signify analgesia was detected

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with moderate cancer-related pain (NRS 3-8 and STAS-J 2-3) Patients who agreed to participate in the study and signed informed consent form

Exclusion criteria

Exclusion criteria: Patients with previously receiving strong opioid analgesic administration. Patient with severe cancer-related pain (NRS 9-10 and/or STAS-J 4)

Design outcomes

Primary

Measure	Time frame
Analgesic effects after 2-4weeks later (NRS, STAS-J) Adverse effect rate	—

Secondary

Measure	Time frame
Efficacy rate	—

Countries

Japan

Contacts

Public ContactYasuro Kato

Kansai Electric Power Hospital Department of Palliative Medicine

kato.yasuro@d5.kepco.co.jp06-6458-5821

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026